MAZE — Maze Therapeutics Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Maze Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 168 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 113 | 98.6 | 110 | 143 |
| Operating Profit | -113 | -98.6 | 57.6 | -143 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -115 | -100 | 53.4 | -131 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -115 | -100 | 52.2 | -131 |
| Equity in Affiliates | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -115 | -100 | 18.4 | -131 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -115 | -100 | 3.4 | -131 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -2.57 | -2.29 | 0.078 | -3.05 |
| Dividends per Share |